Case
Study
One Myelofibrosis DISCOVERING GROUND-BREAKING THERAPIES FROM OXFORD UNIVERSITY Case
Study
One Myelofibrosis DISCOVERING GROUND-BREAKING THERAPIES FROM OXFORD UNIVERSITY Case
Study
Two Myocarditis Ground breaking research from Oxford University Case
Study
Two Myocarditis Ground breaking research from Oxford University Case
Study
Three Next Generation Antibiotics Ground breaking research from Oxford University Case
Study
Three Next Generation Antibiotics Ground breaking research from Oxford University

ACCELERATING OXFORD DRUG DISCOVERY Recently expanded and open for new calls 32 projects funded DISCOVER MORE > ACCELERATING OXFORD DRUG DISCOVERY Recently expanded and open for new calls 32 projects funded DISCOVER MORE > ACCELERATING OXFORD DRUG DISCOVERY Recently expanded and open for new calls 32 projects funded DISCOVER MORE >|

APPLICATIONS

LAB282 welcomes ad hoc applications, as well as applications in response to specific calls that it may issue.

MORE

LAB282 SUPPORT

LAB282 helps academics access a wide range of early stage drug discovery and development capabilities.

MORE

LAB282 TEAM

Thomas Hanke, our Expert in Residence, works in cross-functional teams setting directions and fostering innovation.

MORE

Lab282 Partners

LAB282 is a partnership between the University of Oxford, Oxford University Innovation Ltd, Oxford Sciences Innovation plc (OSI) and Evotec AG, created to identify and develop new approaches to treating disease.

Privacy Policy | Cookie Policy

© LAB282 2019. All rights reserved LAB282 is a partnership between the University of Oxford, Oxford University Innovation Ltd, Oxford Sciences Innovation plc (OSI) and Evotec AG, created to identify and develop new approaches to treating disease.

Privacy Policy | Cookie Policy

© LAB282 2019. All rights reserved